Evidence map›Paper›PMID 37693406›Full record

ArticlebioRxiv : the preprint server for biology2025

Rab7a is required to degrade select blood-brain barrier junctional proteins after ischemic stroke.

Azzurra Cottarelli, Danny Jamoul, Mary Claire Tuohy, Sanjid Shahriar, Michael Glendinning, Grace Prochilo, Aimee L Edinger, Ahmet Arac, Dritan Agalliu

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Azzurra CottarelliDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID 0000-0003-4525-2028
Danny JamoulDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Mary Claire TuohyDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Sanjid ShahriarDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Michael GlendinningDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Grace ProchiloDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Aimee L EdingerDepartments of Developmental and Cell Biology and Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.
Ahmet AracDepartment of Neurology, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, 90095, USA.
Dritan AgalliuDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Columbia University Irving Medical Center · USUniversity of California, Irvine · USUniversity of California, Los Angeles · US

Funding

Neuronal Regulation of Vascular Development and Maturation in the RetinaR01EY033994 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dritan Agalliu · 2022 to 2026
$2.3M
Assessing the effects of peripheral immune activation on the NVU following TBI using a vascularized and perfused human blood/BBB modelR33HL159949 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, LIS, RAPHAEL · 2023 to 2025
$2.2M
Cellular and humoral immune mechanisms underlying neurovascular dysfunction in autoimmune encephalitisR01MH112849 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, CUTFORTH, TYLER · 2017 to 2020
$2.1M
Assessing the effects of peripheral immune activation on the NVU following TBI using avascularized and perfused human blood/BBB model.R61HL159949 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, LIS, RAPHAEL · 2021 to 2022
$1.9M
Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's diseaseRF1AG078352 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, SPROUL, ANDREW ALEXANDER · 2022 to 2024
$1.4M
Regulation of nutrient access by growth factors and mTORK08CA100526 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EDINGER, AIMEE L · 2003 to 2007
$689k
Elucidating the role of RXRA in the myeloid lineage in post-infectious basal ganglia encephalitisR21NS130265 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN · 2022 to 2022
$442k
The role of autophagy in the neurovascular unit for the physiological response to stress.R21NS118891 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, YAMAMOTO, AI · 2020 to 2020
$438k
NCI NIH HHS K08 CA100526NEI NIH HHS R01 EY033994NHLBI NIH HHS R33 HL159949NHLBI NIH HHS R61 HL159949NIA NIH HHS RF1 AG078352NIMH NIH HHS R01 MH112849NINDS NIH HHS R21 NS118891NINDS NIH HHS R21 NS130265
6 · The paper itself

Abstract

Adherens (AJ) and tight junction (TJ) integrity is critical for blood-brain barrier (BBB) function in the healthy brain. Junction disassembly due to degradation of AJ and TJ proteins leads to acute BBB dysfunction after ischemic stroke, but the mechanisms are not fully understood. Here, we show that endothelial cell deletion of Rab7a, a small GTPase crucial for protein degradation through the endolysosomal system, reduces acute BBB dysfunction and improves neuronal health in mice after ischemic stroke by preventing degradation of select junctional proteins and preserving TJ structural morphology. Two pro-inflammatory cytokines, TNFα and IL1β, that trigger barrier disruption in brain endothelial cells (BECs)

Indexed as

adherens junctionsblood-brain barrierClaudin-5cytokinesF-actininflammationischemic strokeRab7atight junctionsVE-CadherinZO-1

Identifiers

PMID37693406
PMCPMC10491261
OpenAlexW4386273930

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.